KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) FCF Margin (2017 - 2025)

Historic FCF Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 43.84%.

  • Biomarin Pharmaceutical's FCF Margin rose 166100.0% to 43.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.89%, marking a year-over-year increase of 152700.0%. This contributed to the annual value of 17.08% for FY2024, which is 144900.0% up from last year.
  • Biomarin Pharmaceutical's FCF Margin amounted to 43.84% in Q3 2025, which was up 166100.0% from 20.37% recorded in Q2 2025.
  • Biomarin Pharmaceutical's FCF Margin's 5-year high stood at 43.84% during Q3 2025, with a 5-year trough of 16.5% in Q1 2023.
  • For the 5-year period, Biomarin Pharmaceutical's FCF Margin averaged around 11.55%, with its median value being 13.68% (2024).
  • In the last 5 years, Biomarin Pharmaceutical's FCF Margin surged by 292100bps in 2021 and then plummeted by -324000bps in 2022.
  • Biomarin Pharmaceutical's FCF Margin (Quarter) stood at 3.9% in 2021, then crashed by -38bps to 5.38% in 2022, then surged by 96bps to 0.22% in 2023, then soared by 10116bps to 22.23% in 2024, then skyrocketed by 97bps to 43.84% in 2025.
  • Its FCF Margin stands at 43.84% for Q3 2025, versus 20.37% for Q2 2025 and 21.15% for Q1 2025.